A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Clinical Study of ToripalimabJS001 Combined With Donafenib in Patients With Advanced Hepatocellular Carcinoma
Latest Information Update: 30 Nov 2022
At a glance
- Drugs Donafenib (Primary) ; Toripalimab (Primary)
- Indications Liver cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Suzhou Zelgen Biopharmaceuticals
- 28 Nov 2022 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 28 Nov 2022 Planned primary completion date changed from 1 Dec 2022 to 1 Dec 2023.
- 30 Apr 2021 Status changed from not yet recruiting to recruiting.